SCHEMBL375798

SCHEMBL375798

Cc1ccc2c(c1)C(=O)c1c(O)ccc(O)c1C2=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.67
MAOA P21397 5/20 0.61
MAOB P27338 2/20 0.61
ELANE P08246 2/20 0.59
MEN1 O00255 7/20 0.57
KMT2A Q03164 7/20 0.57
MAPT P10636 6/20 0.57
TDP1 Q9NUW8 5/20 0.52
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 5/20 0.52
MAPK1 P28482 5/20 0.52
RECQL P46063 5/20 0.52
HPGD P15428 4/20 0.52
CYP3A4 P08684 4/20 0.52
USP2 O75604 3/20 0.52
BRCA1 P38398 3/20 0.52
ALOX15 P16050 3/20 0.52
HSD17B10 Q99714 3/20 0.52
THRB P10828 2/20 0.52
TP53 P04637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31265528 1.00 LCK (0.67) LCKMAOAMAOBELANEMEN1
SCHEMBL27796804 0.85 TTR (0.70) LCKMAOAMAOBELANEMEN1
SCHEMBL24148896 0.85 TTR (0.70) LCKMAOAMAOBELANEMEN1
SCHEMBL5981382 0.84 ELANE (0.69) LCKMAOAMAOBELANEMEN1
SCHEMBL30610009 0.84 ELANE (0.69) LCKMAOAMAOBELANEMEN1
SCHEMBL29405931 0.84 ELANE (0.69) LCKMAOAMAOBELANEMEN1
SCHEMBL29435136 0.84 ELANE (0.69) LCKMAOAMAOBELANEMEN1
SCHEMBL9353826 0.81 MAOA (0.68) LCKMAOAMAOBELANEMEN1
SCHEMBL11080514 0.81 LCK (0.68) LCKMAOAMAOBELANEMEN1
SCHEMBL7172505 0.80 LCK (1.00) LCKMAOAMAOBELANEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US claimed
EP-1538154-B1 Quencher composition comprising anthraquinone moieties EXIQON AS (DK) 2008-12-31 EP claimed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US disclosed
US-20140227689-A1 NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS EXIQON A/S (DK) 2014-08-14 US disclosed
US-8394512-B2 Phosphaphenanthrene compounds and organic light emitting diode using the same INKTEC CO., LTD. (KR) 2013-03-12 US disclosed
US-8394512-B2 Phosphaphenanthrene compounds and organic light emitting diode using the same INKTEC CO., LTD. (KR) 2013-03-12 US disclosed
US-8394512-B2 Phosphaphenanthrene compounds and organic light emitting diode using the same INKTEC CO., LTD. (KR) 2013-03-12 US disclosed
US-8383344-B2 Methods for quantification of microRNAs and small interfering RNAs EXIQON A/S (DK) 2013-02-26 US disclosed
CN-1961081-B Methods for quantification of microRNA and small interfering RNA EXIQON AS 2012-09-05 CN disclosed
US-8192937-B2 Methods for quantification of microRNAs and small interfering RNAs EXIQON A/S (DK) 2012-06-05 US disclosed
EP-1735459-B1 METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS EXIQON AS (DK) 2012-01-25 EP disclosed
WO-2005098029-A2 METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS EXIQON A/S (DK) 2005-10-20 WO disclosed
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties QIAGEN GMBH (DE) 2005-10-13 US disclosed
EP-1538154-A1 Quencher composition comprising anthraquinone moieties Exiqon A/S (DK) 2005-06-08 EP disclosed
US-5484935-A Pharmaceutical compounds LILLY INDUSTRIES LIMITED (GB) 1996-01-16 US disclosed
EP-0638562-A1 Anthraquinone derivatives useful in the treatment of cancer and osteoartritis LILLY INDUSTRIES LIMITED (GB) 1995-02-15 EP disclosed
EP-0125311-B1 POLYESTERS CONTAINING COPOLYMERIZED, ANTHRAQUINONE COLORANT COMPOUNDS CONTAINING SULFONAMIDO GROUPS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-01-20 EP disclosed
EP-0125311-A1 POLYESTERS CONTAINING COPOLYMERIZED, ANTHRAQUINONE COLORANT COMPOUNDS CONTAINING SULFONAMIDO GROUPS. EASTMAN KODAK CO (US) 1984-11-21 EP disclosed
WO-1984002136-A2 POLYESTERS CONTAINING COPOLYMERIZED, ANTHRAQUINONE COLORANT COMPOUNDS CONTAINING SULFONAMIDO GROUPS EASTMAN KODAK CO (US) 1984-06-07 WO disclosed
US-4403092-A COLORFAST FOOD CONTAINERS EASTMAN KODAK COMPANY (US) 1983-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties ANXA5, SUN2, ANXA3 LCK 4263/4885MAOA 4699/4885MAOB 4296/4885
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION TOMM70, TOMM34, TIMM50 LCK 4305/4885MAOA 3628/4885MAOB 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.